Sissung Tristan M, Peer Cody J, Korde Neha, Mailankody Sham, Kazandjian Dickran, Venzon David J, Landgren Ola, Figg William D
Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, 9000 Rockville Pike, Building 10, Rm 5A01, Bethesda, MD, 20892, USA.
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.
The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis agents, we explored associations between such polymorphisms and CRd clinical response. The VEGF-1498C>T (rs833061) and VEGFR2 V297I (rs2305948) were associated with CRd response (OR ≤ 0.10, P ≤ 0.009), whereas VEGF-1498C>T and VEGFR2 Q472H (rs1870377) were associated with minimum residual disease negativity (P ≤ 0.023). As these SNPs were not associated with disease parameters (e.g., plasma VEGF, albumin, or beta-2-microglobin concentration), data suggest these SNPs may be markers of CRd response.
卡非佐米、来那度胺和地塞米松联合用药（CRd）已在新诊断的多发性骨髓瘤患者中诱导出深度缓解。虽然血管内皮生长因子（VEGF）途径多态性与抗血管生成药物的临床结局相关，但我们探讨了此类多态性与CRd临床反应之间的关联。VEGF - 1498C>T（rs833061）和VEGFR2 V297I（rs2305948）与CRd反应相关（比值比≤0.10，P≤0.009），而VEGF - 1498C>T和VEGFR2 Q472H（rs1870377）与最小残留病阴性相关（P≤0.023）。由于这些单核苷酸多态性与疾病参数（如血浆VEGF、白蛋白或β2微球蛋白浓度）无关，数据表明这些单核苷酸多态性可能是CRd反应的标志物。
